非16/18HPV阳性、TCT正常患者转诊阴道镜的时机探讨
Journal: Basic Medical Theory Research DOI: 10.12238/bmtr.v6i6.10987
Abstract
目的：探讨感染非16/18高危型人乳头瘤病毒(HR-HPV)患者进展为高级别鳞状上皮内病变(HSIL)及宫颈癌的独立危险因素。方法：收集2020年1月至2023年12月在保定市第一中心医院行阴道镜活检的TCT正常、非16/18HR-HPV阳性患者的一般资料,依据阴道镜活检病理结果分为HSIL+组及HSIL-组,采用卡方检验比较两组之间的差异,采用Logistic回归分析各因素与HSIL+检出率的相关性。结果：在单因素分析中,宫颈转化区、绝经状态、接触性出血、感染时间与HSIL+检出率有相关性(P＜0.05),多因素Logistic回归分析表明,宫颈转化区、绝经、接触性出血、感染时间与HSIL+检出率有显著相关性(P<0.05)。结论：对于TCT正常、非16/18HR-HPV阳性患者,临床上需对已绝经、转化区3型、有接触性出血及感染时间超过1年的非16/18HR-HPV阳性女性采取更加积极的行动。
Keywords
高危HPV感染；液基薄层细胞学检查；宫颈病变；阴道镜下宫颈活检
Full Text
PDF - Viewed/Downloaded: 0 TimesReferences
[1] Arbyn M,Weiderpass E, Bruni L,etal.Estimates of incid ence and mortality of cervical cancer in 2018: a worldwide analysis[J]. The Lancet Global Health,2020,8(2):e191-e203.
[2] Sung H,Ferlay J,Siegel R L,etal.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldw ide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians,2021,71(3):209-249.
[3] 魏丽惠,李明珠,王悦.《世界卫生组织子宫颈癌癌前病变筛查和治疗指南 (第2版 )》解读[J].中国医学前沿杂志(电子版),2021,13(09):44-48.
[4] 樊凌云,王欢,韩毅敏.人乳头瘤病毒新型检测及分型方法的研究进展[J].现代肿瘤医学,2022,30(03):525-528.
[5] Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: obser vational study[J].bmj,2019,364.
[6] Freire-Salinas J, Benito R, Azueta A, et al. Genotype distribution change after human papillomavirus vaccination in two autonomous communities in Spain[J].Frontiers in Cell ular and Infection Microbiology,2021,11:633162.
[7] 李双,李明珠,丛青,等.人乳头瘤病毒疫苗临床应用中国专家共识[J].协和医学杂志,2021,12(02):189-201.
[8] Elbasha E H,Dasbach E J,Insinga R P. Model for assessing human papillomavirus vaccination strategies[J].Emerging infe ctious diseases,2007,13(1):28-41.
[9] 魏丽惠,赵昀,沈丹华.中国子宫颈癌筛查及异常管理相关问题专家共识(一)[J].中国妇产科临床杂志,2017,18(2):190-192.
[10] Perkins R B, Guido R S, Castle P E, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors[J].Journal of lower genital tract disease,2020,24(2):102-131.
[11] Polman N J, Veldhuijzen N J, Heideman D A M, et al. HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test[J]. British journal of cancer,2017,117(10):1557-1561.
[12] Rijkaart D C,Berkhof J,Van Kemenade F J,etal.Evaluat ion of 14 triage strategies for HPV DNA‐positive women in population-based cervical screening[J].International journal of cancer,2012,130(3):602-610.
[13] 李乔,尹如铁.老年女性宫颈癌筛查现状与展望[J].实用妇产科杂志,2018,34(07):504-506.
[14] 董世庆,陈萃.不同类型宫颈转化区在高危型人乳头瘤病毒感染后的转归比较[J].重庆医学,2023,52(18):2780-2784.
[2] Sung H,Ferlay J,Siegel R L,etal.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldw ide for 36 cancers in 185 countries[J]. CA: a cancer journal for clinicians,2021,71(3):209-249.
[3] 魏丽惠,李明珠,王悦.《世界卫生组织子宫颈癌癌前病变筛查和治疗指南 (第2版 )》解读[J].中国医学前沿杂志(电子版),2021,13(09):44-48.
[4] 樊凌云,王欢,韩毅敏.人乳头瘤病毒新型检测及分型方法的研究进展[J].现代肿瘤医学,2022,30(03):525-528.
[5] Rebolj M, Rimmer J, Denton K, et al. Primary cervical screening with high risk human papillomavirus testing: obser vational study[J].bmj,2019,364.
[6] Freire-Salinas J, Benito R, Azueta A, et al. Genotype distribution change after human papillomavirus vaccination in two autonomous communities in Spain[J].Frontiers in Cell ular and Infection Microbiology,2021,11:633162.
[7] 李双,李明珠,丛青,等.人乳头瘤病毒疫苗临床应用中国专家共识[J].协和医学杂志,2021,12(02):189-201.
[8] Elbasha E H,Dasbach E J,Insinga R P. Model for assessing human papillomavirus vaccination strategies[J].Emerging infe ctious diseases,2007,13(1):28-41.
[9] 魏丽惠,赵昀,沈丹华.中国子宫颈癌筛查及异常管理相关问题专家共识(一)[J].中国妇产科临床杂志,2017,18(2):190-192.
[10] Perkins R B, Guido R S, Castle P E, et al. 2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors[J].Journal of lower genital tract disease,2020,24(2):102-131.
[11] Polman N J, Veldhuijzen N J, Heideman D A M, et al. HPV-positive women with normal cytology remain at increased risk of CIN3 after a negative repeat HPV test[J]. British journal of cancer,2017,117(10):1557-1561.
[12] Rijkaart D C,Berkhof J,Van Kemenade F J,etal.Evaluat ion of 14 triage strategies for HPV DNA‐positive women in population-based cervical screening[J].International journal of cancer,2012,130(3):602-610.
[13] 李乔,尹如铁.老年女性宫颈癌筛查现状与展望[J].实用妇产科杂志,2018,34(07):504-506.
[14] 董世庆,陈萃.不同类型宫颈转化区在高危型人乳头瘤病毒感染后的转归比较[J].重庆医学,2023,52(18):2780-2784.
Copyright © 2024 王佳宇, 刘丽萍, 张雪梅, 申丛珊, 陈丽
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License